Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the IUPAC name 2-{3-[(diaminomethylidene)amino]phenyl}-3-[hydroxy(3-phenylpropyl)phosphoryl]propanoic acid. It contains a guanidine group attached to a phenylene ring, and a phosphonate moiety linked to a hydroxy-substituted phenylalkane side chain. The drug is classified as experimental and does not have an approved therapeutic indication or established clinical use. Its mechanism of action, pharmacological target(s), and potential indications are not described in public databases, suggesting it may be an investigational tool compound or early-stage lead structure[7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-(3-carbamimidamidamidophenyl)-3-[hydroxy(3-phenylpropyl)phosphoryl]propanoic acid.